3Coley WB. II. Contribution to the knowledge of sarcoma. Ann Surg, 1891,14: 199-220. 被引量：1
4Clauberg KW. The immunobiological legacy of Emil von Behring and Paul Ehrlich. Dtsch Med J, 1954,5:138-146.[in undetermined language]. 被引量：1
5Burnet M. Cancer; a biological approach. I. The processes of control. Br Med J, 1957,1 :779-786. 被引量：1
6Thomas L, Lawrence HS. Cellular and humoral aspects of the hypersensitive states. New York: Hoeber-Harper, 1959:529-532. 被引量：1
7Knuth A, Wolfel T, Klehmann E, et al. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci USA, 1989,86:2804-2808. 被引量：1
8Parker GA, Rosenberg SA. Serologic identification of multiple tumor-associated antigens on murine sarcomas. J Natl Cancer Inst, 1977,58:1303-1309. 被引量：1
9Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res, 2009,15:5323-5337. 被引量：1
10Nukaya I, Yasumoto M, Iwasaki T, et al. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor?reactive cytotoxic T lymphocyte. Int J Cancer, 1999,80:92-97. 被引量：1
